SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-060651
Filing Date
2023-11-08
Accepted
2023-11-08 06:30:25
Documents
72
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-20230930.htm   iXBRL 10-Q 1902171
2 EX-31.1 fnch-ex31_1.htm EX-31.1 19636
3 EX-31.2 fnch-ex31_2.htm EX-31.2 19878
4 EX-32.1 fnch-ex32_1.htm EX-32.1 19441
  Complete submission text file 0000950170-23-060651.txt   7128132

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fnch-20230930_def.xml EX-101.DEF 161916
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fnch-20230930_lab.xml EX-101.LAB 392774
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fnch-20230930_pre.xml EX-101.PRE 297571
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fnch-20230930_cal.xml EX-101.CAL 49660
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fnch-20230930.xsd EX-101.SCH 46360
66 EXTRACTED XBRL INSTANCE DOCUMENT fnch-20230930_htm.xml XML 1194742
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 231385865
SIC: 2836 Biological Products, (No Diagnostic Substances)